Aberdeen Group plc Has $28.79 Million Stock Holdings in BioNTech SE Sponsored ADR $BNTX

Aberdeen Group plc decreased its stake in shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX) by 59.6% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 291,907 shares of the company’s stock after selling 430,021 shares during the period. Aberdeen Group plc’s holdings in BioNTech were worth $28,788,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of BNTX. Rhenman & Partners Asset Management AB lifted its position in BioNTech by 0.3% during the second quarter. Rhenman & Partners Asset Management AB now owns 35,870 shares of the company’s stock worth $3,819,000 after acquiring an additional 120 shares during the last quarter. Kennedy Capital Management LLC increased its stake in shares of BioNTech by 0.8% during the second quarter. Kennedy Capital Management LLC now owns 16,422 shares of the company’s stock worth $1,748,000 after purchasing an additional 127 shares during the period. Probity Advisors Inc. lifted its holdings in BioNTech by 5.7% during the 3rd quarter. Probity Advisors Inc. now owns 2,506 shares of the company’s stock worth $247,000 after purchasing an additional 135 shares during the last quarter. Profund Advisors LLC boosted its stake in BioNTech by 3.6% in the 2nd quarter. Profund Advisors LLC now owns 4,309 shares of the company’s stock valued at $459,000 after purchasing an additional 149 shares during the period. Finally, Banco Bilbao Vizcaya Argentaria S.A. grew its holdings in BioNTech by 2.5% in the 2nd quarter. Banco Bilbao Vizcaya Argentaria S.A. now owns 7,653 shares of the company’s stock valued at $822,000 after buying an additional 186 shares in the last quarter. 15.52% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on BNTX shares. Berenberg Bank reissued a “buy” rating on shares of BioNTech in a report on Friday, January 23rd. Jefferies Financial Group reaffirmed a “buy” rating and set a $151.00 price target on shares of BioNTech in a research report on Wednesday, December 3rd. Bank of America cut their price objective on shares of BioNTech from $134.00 to $130.00 and set a “buy” rating for the company in a report on Wednesday, October 22nd. TD Cowen reaffirmed a “hold” rating on shares of BioNTech in a report on Monday, November 3rd. Finally, JPMorgan Chase & Co. dropped their price target on shares of BioNTech from $121.00 to $120.00 and set a “neutral” rating for the company in a research report on Thursday, October 23rd. Eleven research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $140.10.

BioNTech Stock Up 1.1%

Shares of NASDAQ BNTX opened at $106.99 on Wednesday. The company has a market cap of $24.09 billion, a price-to-earnings ratio of -40.68 and a beta of 1.49. The company has a current ratio of 7.12, a quick ratio of 7.02 and a debt-to-equity ratio of 0.01. BioNTech SE Sponsored ADR has a 12 month low of $81.20 and a 12 month high of $124.49. The stock has a 50-day moving average price of $103.34 and a two-hundred day moving average price of $103.48.

BioNTech Profile

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.